DOXYCYCLINE HYCLATE capsule

Doxycycline Hyclate by

Drug Labeling and Warnings

Doxycycline Hyclate by is a Prescription medication manufactured, distributed, or labeled by Apotheca Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method 1,2,4 (broth or agar). The MIC values should be interpreted according to criteria provided in Table 1.

Diffusion techniques

Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method 1,3,4. This procedure uses paper disks impregnated with 30-μg doxycycline to test the susceptibility of microorganisms to doxycycline. The disk diffusion interpretive criteria are provided in Table 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method5. The MIC values obtained should be interpreted according to the criteria provided in Table 1.

Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline
Bacteria *Minimal Inhibitory
Concentration
(mcg/mL) 		Zone Diameter
(mm) 		Agar Dilution
(mcg/mL)
SIRSIRSIR
  • * Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline.
  • † The current absence of resistance isolates precludes defining any results other than "Susceptible". If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.
  • ‡ Gonococci with 30 mcg tetracycline disk zone diameters of <19mm usually indicate a plasmid-mediated tetracycline resistant Neisseria gonorrhoeae isolate. Resistance in these strains should be confirmed by a dilution test (MIC ≥ 16 mcg/mL)
    • Acinetobacter spp.
      Doxycycline≤48≥16≥1310-12≤9---
      Tetracycline≤48≥16≥1512-14≤11---
    Anaerobes
      Tetracycline------≤48≥16
    Bacillus anthracis†
      Doxycycline≤1--------
      Tetracycline≤1--------
    Brucella species †
      Doxycycline≤1--------
      Tetracycline≤1--------
    Enterobacteriaceae
      Doxycycline≤48≥16≥1411-13≤10---
      Tetracycline≤48≥16≥1512-14≤11---
    Franciscella tularensis†
      Doxycycline≤4--------
      Tetracycline≤4--------
    Haemophilus influenzae
      Tetracycline≤24≥8≥2926-28≤25---
    Mycoplasma pneumoniae†
      Tetracycline------≤2--
    Nocardiae and other aerobic Actinomyces species †
      Doxycycline≤12-4≥8------
    Neisseria gonorrhoeae‡
      Tetracycline---≥3831-37≤30≤0.250.5-1≥2
    Streptococcus pneumoniae
      Doxycycline<0.250.5>1≥2825-27≤24---
      Tetracycline≤12≥4≥2825-27≤24---
    Vibrio cholerae
      Doxycycline≤48≥16------
      Tetracycline≤48≥16------
    Yersinia pestis
      Doxycycline≤48≥16------
      Tetracycline≤48≥16------
    Ureaplasma urealyticum
      Tetracycline------≤1-≥2

    A report of "Susceptible" (S) indicates that the antimicrobial drug is likely to inhibit growth of the microorganism if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentrations usually achievable at the infection site; other therapy should be selected.

    Quality Control

    Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test 1,2,3,4,5,6,7. Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg doxycycline disk the criteria noted in Table 2 should be achieved.

    Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline
    QC StrainMinimal Inhibitory Concentration
    (mcg/mL)     		Zone Diameter
    (mm)     		Agar Dilution
    (mcg/mL)
    Enterococcus faecalis ATCC 29212
      Doxycycline2 - 8--
      Tetracycline8 - 32--
    Escherichia coli ATCC 25922
      Doxycycline0.5 - 218 - 24-
      Tetracycline0.5 - 218 - 25-
    Eubacteria lentum ATCC 43055
      Doxycycline2 - 16--
    Haemophilus influenzae ATCC 49247
      Tetracycline4 - 3214 - 22-
    Neisseria gonorrhoeae ATCC 49226
      Tetracycline-30 - 420.25 - 1
    Staphylococcus aureus ATCC 25923
      Doxycycline-23 - 29-
      Tetracycline-24 - 30-
    Staphylococcus aureus ATCC 29213
      Doxycycline0.12 - 0.5--
      Tetracycline0.12 - 1--
    Streptococcus pneumoniae ATCC 49619
      Doxycycline0.015 - 0.1225 - 34-
      Tetracycline0.06 - 0.527 - 31-
    Bacteroides fragilis ATCC 25285
      Tetracycline--0.12 - 0.5
    Bacteroides thetaiotaomicron ATCC 29741
      Doxycycline2 - 16--
      Tetracycline--8 - 32
    Mycoplasma pneumoniae ATCC 29342
      Tetracycline0.06 - 0.5-0.06 - 0.5
    Ureaplasma urealyticum ATCC 33175
      Tetracycline--≥8
  • INDICATIONS AND USAGE

    To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Capsules and other antibacterial drugs, Doxycycline Hyclate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Treatment

    Doxycycline is indicated for the treatment of the following infections:

    • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.
    • Respiratory tract infections caused by Mycoplasma pneumoniae.
    • Lymphogranuloma venereum caused by Chlamydia trachomatis.
    • Psittacosis (ornithosis) caused by Chlamydophila psittaci.
    • Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.
    • Inclusion conjunctivitis caused by Chlamydia trachomatis.
    • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis.
    • Nongonococcal urethritis caused by Ureaplasma urealyticum.
    • Relapsing fever due to Borrelia recurrentis.

    Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:

    • Chancroid caused by Haemophilus ducreyi.
    • Plague due to Yersinia pestis.
    • Tularemia due to Francisella tularensis.
    • Cholera caused by Vibrio cholerae.
    • Campylobacter fetus infections caused by Campylobacter fetus.
    • Brucellosis due to Brucella species (in conjunction with streptomycin).
    • Bartonellosis due to Bartonella bacilliformis.
    • Granuloma inguinale caused by Klebsiella granulomatis.

    Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

    Doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug:

    • Escherichia coli.
    • Enterobacter aerogenes.
    • Shigella species.
    • Acinetobacter species.
    • Respiratory tract infections caused by Haemophilus influenzae.
    • Respiratory tract and urinary tract infections caused by Klebsiella species.

    Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

    • Upper respiratory infections caused by Streptococcus pneumoniae.
    • Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

    When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:

    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
    • Syphilis caused by Treponema pallidum.
    • Yaws caused by Treponema pallidum subspecies pertenue.
    • Listeriosis due to Listeria monocytogenes.
    • Vincent's infection caused by Fusobacterium fusiforme.
    • Actinomycosis caused by Actinomyces israelii.
    • Infections caused by Clostridium species.

    In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.

    In severe acne, doxycycline may be useful adjunctive therapy.

    Prophylaxis

    Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. (See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.)

  • CONTRAINDICATIONS

    This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

  • WARNINGS

    THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR ANTHRAX, INCLUDING INHALATIONAL ANTHRAX (POST-EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Doxycycline Hyclate Capsules, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing use of antibacterial drugs not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including Doxycycline Hyclate Capsules. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and Doxycycline Hyclate Capsules should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

    Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

    All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

    Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

    The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

    Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

  • PRECAUTIONS

    General

    As with other antibacterial drugs, use of Doxycycline may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, Doxycycline Hyclate Capsules should be discontinued and appropriate therapy instituted.

    Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy, when indicated.

    Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains.

    Doxycycline does not suppress P. falciparum's sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.

    Prescribing Doxycycline Hyclate Capsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    Information For Patients

    Patients taking doxycycline for malaria prophylaxis should be advised:

    1. that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria.
    2. to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (e.g., staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).
    3. that doxycycline prophylaxis:
      • should begin 1–2 days before travel to the malarious area,
      • should be continued daily while in the malarious area and after leaving the malarious area,
      • should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,
      • should not exceed 4 months.

    All patients taking doxycycline should be advised:

    1. to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruption, etc.) occurs. Sunscreen or sunblock should be considered. (See WARNINGS.)
    2. to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)
    3. that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See DRUG INTERACTIONS.)
    4. that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See DRUG INTERACTIONS.)
    5. that the use of doxycycline might increase the incidence of vaginal candidiasis.

    Patients should be counseled that antibacterial drugs, including Doxycycline Hyclate Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Doxycycline Hyclate Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Doxycycline Hyclate Capsules or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibacterial drugs, which usually ends when the antibacterials are discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.

    Laboratory Tests

    In venereal disease, when co-existent syphilis is suspected, dark field examinations should be done before treatment is started and the blood serology repeated monthly for at least 4 months.

    In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies, should be performed.

    Drug Interactions

    Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

    Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

    Absorption of tetracyclines is impaired by bismuth subsalicylate.

    Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

    The concurrent use of tetracycline and Penthrane ® (methoxyflurane) has been reported to result in fatal renal toxicity.

    Concurrent use of tetracycline may render oral contraceptives less effective.

    Drug/Laboratory Test Interactions

    False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

    Carcinogenesis, Mutagenesis, Impairment Of Fertility

    Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibacterial drugs, oxytetracycline (adrenal and pituitary tumors), and minocycline (thyroid tumors).

    Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in in vitro mammalian cell assays have been reported for related antibacterial drugs (tetracycline, oxytetracycline).

    Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.

    Pregnancy

    Teratogenic Effects

    Pregnancy Category D

    There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women, such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS -the Teratogen Information System-concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no riska. A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and fifty-six (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases b.

    A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age c.

    Nonteratogenic Effects

    (See WARNINGS.)

    Labor and Delivery

    The effect of tetracyclines on labor and delivery is unknown.

    Nursing Mothers

    Tetracyclines are excreted in human milk; however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown d. Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See WARNINGS.)

    Pediatric Use

    See WARNINGS and DOSAGE AND ADMINISTRATION.

  • ADVERSE REACTIONS

    Due to oral doxycycline's virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:

    Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported rarely. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION.)

    Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.)

    Renal toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS.)

    Immune: Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, and drug rash with eosinophilia and systemic symptoms (DRESS).

    Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.

    Other: bulging fontanels in infants and intracranial hypertension in adults. (See PRECAUTIONS- General.)

    When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function studies are known to occur.

    To report suspected ADVERSE REACTIONS, contact Cipla Limited at 1-866-604-3268 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • OVERDOSAGE

    In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.

  • DOSAGE AND ADMINISTRATION

    THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day.

    In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.

    For children above eight years of age: The recommended dosage schedule for children weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe infections, up to 2 mg/lb of body weight may be used. For children over 100 lb the usual adult dose should be used.

    The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.

    When used in streptococcal infections, therapy should be continued for 10 days.

    Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)

    If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk.

    Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment.

    Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. The dose may be administered with food, including milk or carbonated beverage, as required.

    Uncomplicated urethral, endocervical, or rectal infection in adults caused by Chlamydia trachomatis: 100 mg, by mouth twice a day for 7 days.

    Nongonococcal urethritis (NGU) caused by C. trachomatis or U. urealyticum: 100 mg by mouth, twice a day for 7 days.

    Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 2 weeks.

    Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.

    Acute epididymo-orchitis caused by N. gonorrhoeae: 100 mg, by mouth, twice a day for at least 10 days.

    Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice a day for at least 10 days.

    For prophylaxis of malaria: For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1–2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.

    Inhalational anthrax (post-exposure):

    1. ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days.
    2. CHILDREN: weighing less than 100 lb (45 kg); 1 mg/lb (2.2 mg/kg) of body weight by mouth, twice a day for 60 days. Children weighing 100 lb or more should receive the adult dose.
  • HOW SUPPLIED

    Doxycycline Hyclate Capsules, USP 100 mg are available as a light blue capsule filled with yellow powder imprinted with "2985" containing Doxycycline Hyclate, equivalent to 100 mg of doxycycline. They are supplied as follows:

    NDC: 12634-169-00 Bottles of 10

    NDC: 12634-169-01 Bottles of 100

    NDC: 12634-169-09 Bottles of 35

    NDC: 12634-169-12 Bottles of 120

    NDC: 12634-169-18 Bottles of 180

    NDC: 12634-169-40 Bottles of 40

    NDC: 12634-169-42 Bottles of 42

    NDC: 12634-169-45 Bottles of 45

    NDC: 12634-169-50 Bottles of 50

    NDC: 12634-169-52 Blister Pack of 12

    NDC: 12634-169-54 Blister Pack of 14

    NDC: 12634-169-57 Blister Pack of 20

    NDC: 12634-169-59 Blister Pack of 30

    NDC: 12634-169-60 Bottles of 60

    NDC: 12634-169-61 Blister Pack of 10

    NDC: 12634-169-63 Blister Pack of 3

    NDC: 12634-169-66 Blister Pack of 6

    NDC: 12634-169-67 Blister Pack of 7

    NDC: 12634-169-69 Blister Pack of 9

    NDC: 12634-169-71 Bottles of 30

    NDC: 12634-169-74 Bottles of 24

    NDC: 12634-169-78 Bottles of 28

    NDC: 12634-169-79 Bottles of 25

    NDC: 12634-169-80 Bottles of 20

    NDC: 12634-169-81 Bottles of 21

    NDC: 12634-169-82 Bottles of 12

    NDC: 12634-169-84 Bottles of 14

    NDC: 12634-169-85 Bottles of 15

    NDC: 12634-169-90 Bottles of 90

    NDC: 12634-169-91 Blister Pack of 1

    NDC: 12634-169-92 Bottles of 2

    NDC: 12634-169-93 Bottles of 3

    NDC: 12634-169-94 Bottles of 4

    NDC: 12634-169-95 Bottles of 5

    NDC: 12634-169-96 Bottles of 6

    NDC: 12634-169-97 Bottles of 7

    NDC: 12634-169-98 Bottles of 8

    NDC: 12634-169-99 Bottles of 9

    Dispense in a tight, light resistant container as defined in the USP, with a child resistant closure (as required).

    Store at 20° to 25° C (68° to 77° F) (see USP controlled room temperature)

  • ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY

    Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.

    Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

    Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

  • REFERENCES

  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    Cipla USA, Inc.

    9100 S. Dadeland Blvd.

    Suite 1500 Miami, FL 33156

    Made in USA

    Rev. 01 10/2014

    Repackaged & Distributed by:

    Apotheca Inc.

    Phoenix, AZ 85006

  • PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label

    NDC: 12634-169-80

    Rx ONLY

    Doxycycline

    Hyclate

    Capsules USP

    100 mg*

    20 Capsules

    label

  • INGREDIENTS AND APPEARANCE
    DOXYCYCLINE HYCLATE 
    doxycycline hyclate capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 12634-169(NDC: 69097-226)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862) DOXYCYCLINE ANHYDROUS100 mg
    Inactive Ingredients
    Ingredient NameStrength
    ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    HYPROMELLOSES (UNII: 3NXW29V3WO)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    METHYLCELLULOSE (400 MPA.S) (UNII: O0GN6F9B2Y)  
    Product Characteristics
    Colorblue (light blue) Scoreno score
    ShapeCAPSULESize21mm
    FlavorImprint Code 2985
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 12634-169-0010 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    2NDC: 12634-169-01100 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    3NDC: 12634-169-0935 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    4NDC: 12634-169-12120 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    5NDC: 12634-169-18180 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    6NDC: 12634-169-4040 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    7NDC: 12634-169-4242 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    8NDC: 12634-169-4545 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    9NDC: 12634-169-5050 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    10NDC: 12634-169-5212 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    11NDC: 12634-169-5414 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    12NDC: 12634-169-5720 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    13NDC: 12634-169-5930 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    14NDC: 12634-169-6060 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    15NDC: 12634-169-6110 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    16NDC: 12634-169-633 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    17NDC: 12634-169-666 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    18NDC: 12634-169-677 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    19NDC: 12634-169-699 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    20NDC: 12634-169-7130 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    21NDC: 12634-169-7424 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    22NDC: 12634-169-7828 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    23NDC: 12634-169-7925 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    24NDC: 12634-169-8020 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    25NDC: 12634-169-8121 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    26NDC: 12634-169-8212 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    27NDC: 12634-169-8414 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    28NDC: 12634-169-8515 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    29NDC: 12634-169-9090 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    30NDC: 12634-169-911 in 1 BLISTER PACK; Type 0: Not a Combination Product01/24/2017
    31NDC: 12634-169-922 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    32NDC: 12634-169-933 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    33NDC: 12634-169-944 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    34NDC: 12634-169-955 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    35NDC: 12634-169-966 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    36NDC: 12634-169-977 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    37NDC: 12634-169-988 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    38NDC: 12634-169-999 in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06250009/11/1984
    Labeler - Apotheca Inc. (051457844)
    Establishment
    NameAddressID/FEIBusiness Operations
    Apotheca Inc.051457844relabel(12634-169) , repack(12634-169)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.